Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,131–1,140 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1131
- Medicine slug
- omeprazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 280
- Source count
- 135
- Agreement rate
- 1
- Recorded readings
30 to 40%
- Numeric value
- 30
- Unit
- %
- Source records
- 135
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 135 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a09ce48-7139-4fc7-9b6e-439459c8e866 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4ecc1e-5180-f75e-e063-6394a90a51a6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b83329ac-a65e-b3af-a3fb-c5a6c740e5e7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72fb11b6-b08c-2f02-d82b-f60f52394903 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b379ef-7982-434d-9e6b-e01cd2b398d2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f77efc97-2565-38ab-e053-6394a90aebda (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40f66cac-bc23-43f9-9966-87cce458c996 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a17e415e-a559-4a8d-a455-699184a01523 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b19d724-821b-61dc-e063-6294a90aa4d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d6e07d1-38b1-f2ab-e063-6294a90a34ac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17ccdbe0-19c1-498d-8e81-578be549b4e5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205652e1-7fbc-4b6a-bbd6-2fd346d812df (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f5502a-2e63-4f2a-a3ba-ddc5bd403051 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8bf92c9-1bab-7985-e053-2995a90a0225 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:516170d4-4913-4577-a2d2-f5c52d1e79c6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c311c1b9-8ec2-4ac0-baa2-a5063fba2d80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44349466-73ea-4053-8ff6-5b4b7372c9cd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1318a1c1-222d-471a-92d6-3632c82fb999 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b129fe93-c8a2-4ae8-ad1b-8f9ae5779b68 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a656a059-2b1a-44b3-85f8-af278032b54c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9724601b-bb12-4eb2-bc2e-0532976bf5d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9378c870-f2cc-4a60-b0fd-08a4d43857bc (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85afda-6b0c-d657-e053-2a95a90afb4b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1a6f05-ae3e-4f29-bc2d-8e9f51e5fe3e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded71262-d17f-3799-e053-2995a90a5427 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:603d2d06-c5e8-4378-a422-8dca1a410af7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ea9a6f3-b756-4cdf-b3db-f666a2c17d66 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61eab342-61fd-471f-8f70-95f9cbca0097 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3724b8f7-52ff-a5f8-e063-6294a90acf20 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa8fc2ea-3942-453b-bc19-1e4b14ba6926 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb34cff-59c5-4411-b587-10207ffb58c4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f13fd38-dc73-4072-bdc9-9474704a4121 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d99b4fd-49b3-403d-96a4-0cceda85a95c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ef8d55f-6cae-4b58-844b-968d8e5b8c24 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afda9d2c-b141-4c32-a5b4-e850974b30a3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dcf0b2-4fa2-023a-e053-2995a90a183a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dd5d63-1376-1ff7-e053-2a95a90a1d94 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df1a4294-3893-4a11-b4d5-f3536678087e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8090d4c3-3184-7812-53d7-aa30e14b79d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db9f071b-85f4-061f-e053-2995a90a3ff5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a19ce586-59b7-4c2e-9e8d-12e8f0f058e2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:062800b1-790a-41c3-a8be-94143d2c7fb6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30955530-56d2-174d-e063-6294a90a413c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d8be3f-ba13-4897-9ceb-f8ac6ccc1624 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:581d1c3d-457a-41f2-8db0-5b6219cdcb09 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1e0c8fc-1f15-45a4-a80f-653a1dae5e56 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e5d1b21-6b32-0c8d-e063-6294a90a8431 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665e9877-85ac-fdb6-54ac-1c47941ceab8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38bd8e13-591e-f11b-7d8a-11717c56493c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76c23d5-26b6-cfb2-e053-6294a90aea42 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63b3982a-b541-4b0d-99d4-93a673e57d46 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07af8c9-559c-5a93-e053-2a95a90a2c63 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:319d990e-161b-4c16-b026-f55c413c7e8f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ac077f-3873-4087-96d0-89049161dea9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96104ea6-c08f-40b5-83f5-d840b317f1fd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fa6afcf-33b3-3115-e053-2a91aa0abd0b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b1c61b-d4fe-433d-ad31-0b11758976fa (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed9895ae-3d18-434c-8b56-47bccdc8fe6d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50115204-74f7-17c1-e063-6394a90ab665 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b3918c-a66e-4277-8b8f-b7ece93fa7db (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa0395a7-4353-4d64-9de8-d15857a7031c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:530a8a66-48ad-474f-b170-c6fac95753ec (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:064b1418-0f42-4b18-9dee-cda40c5e1fca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0dc4ffa-db18-4871-9d36-51d02e3b2bd9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fc5065c-5850-469b-b357-fa4df30a8f78 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9786b04f-f827-460b-91bc-c0ac967f95dd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe7d3352-d53f-4046-92ed-1eb5c917fbee (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1249c42d-6358-48b3-8fe0-10333c7f501d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f873dc20-c817-5e4f-e053-6394a90a04f2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1276463-7357-45b5-9f7e-8d3c4a550ff4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb57c13-25ed-70bc-e063-6294a90afdac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40a75dc7-49b7-5c9d-6c5f-d4682ec6922e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40b4e1b6-f64d-44d5-bfc2-0cb8f78d9e67 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bda70ae-c3f6-450b-892f-6814795dd6ca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8991d464-7abc-4350-e053-2995a90a4ea7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92201fb1-4570-42db-8da3-3b8c0e291d32 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22ceb2-2c34-43c3-9a35-2589c9078741 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4562da8-9d94-4417-9f80-c1ffd4247259 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1f20429-cfaa-420b-a65a-271be37eb799 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a53ea447-add5-4ed5-aa7e-975b13d90e75 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7491dd-19f5-42e0-b901-7ba71a3820c7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0f61a89-700d-481d-9255-6f9a9afa7025 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85e324-ef9f-196c-e053-2995a90a384e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdc6809-3b1b-046a-e063-6394a90ae02a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd71fd8-3f36-46a1-bc76-53f6820d42a2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a9baece-03be-6c77-e063-6394a90a7032 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6c22be1-659d-4e71-b292-701e27da201b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcaadc8c-32d1-476f-b821-973c012b7fa7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded0df8b-1813-4595-ac2b-5499704bfd48 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c6e00a2-31e8-4e84-928d-80e69a5fc634 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aae3bf9f-5d05-889f-e053-2995a90a5ff2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e99b78b-7fb8-4514-a3db-58e59cd429d8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18f5a7cc-40d8-4aeb-a601-47bc9024f130 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39e3b45a-8e9b-49d6-976a-6668f4e27649 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:934601b6-fbba-43c4-a8ef-7a7dfe9f9a51 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:487ff32f-943e-458b-b898-bd7b0290cc49 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee0598a1-0e5e-40ff-ad88-b0adfc533ca0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb314cb-6291-422c-98ff-24d8449992f6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557d4c2c-5541-3a51-e063-6394a90ad278 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c41bcfa-b08b-3ac3-e053-2a95a90ae1c0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0344268f-d8e6-48d5-b1e1-f750ed1d8a52 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27b3518-d5c1-1229-e053-2a95a90ab56f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af707c0a-5193-3f83-e053-2995a90a78ef (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a806da8c-5f84-454d-966c-da1c48710f80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8f2e604-74fa-4205-b41f-32401e2dc59e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5564c9dc-6f99-6639-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad675ef6-5377-b9f2-e053-2995a90a06e9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be616c4-1b9a-5654-e054-00144ff88e88 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a1fb3c-f040-2e39-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4cd8ed1-d9d3-5b57-e053-2995a90a9f3c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f226173f-4318-43e0-847a-8ea237e6b41d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28515ff8-379d-5356-e063-6394a90af3f3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab3d84c-c563-6f04-e063-6394a90a34ff (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43090803-37de-77e3-e063-6294a90a8c43 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd1acb8-12dc-70b7-e063-6394a90a0399 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a3fbc9-00c6-ad83-e063-6294a90ae1ad (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288bdd5e-a0ac-4c5c-abe0-93183a28dcdd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3038133-8bb2-044e-e053-2995a90a6e7d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f5c91e6-6377-ca94-e063-6294a90a2f99 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0cf466-f9e8-390e-e063-6294a90a2ed8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dcd48e4-9ffc-9cc2-e063-6294a90ae17e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30e58465-c5d2-4925-85bb-53faa6135c5c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ad413ed-a21b-4f8b-9322-8fbb813b14d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17664f71-154a-47c6-b83c-b349bbc8a98f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b188d97-f1b3-468d-9818-b8333bf24b5a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30-40% at doses of 20-40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c99e189-93c0-4461-82c2-4521e6c4d514 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d925ca6-83f1-4263-8218-4bf7cc8ceb39 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:253451a6-02a9-4b27-aed7-f3dbc2e09682 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e87d2206-9c06-438c-947b-10b29a879d7b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bab55f83-ba03-49a0-842a-19c9976b7fe8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e235ef89-3592-4ca1-8c13-d7ce84b1001c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4720cc17-013e-074e-e063-6294a90ac1f4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f6ad19-ff6a-7cd3-e053-6294a90ae1bf (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5af5f4b-17be-7245-b281-f27c87831242 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9359e826-5263-44fc-8dd3-9d0852fe42d6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absolute bioavailability (compared with intravenous administration) is about 30 to 40% at doses of 20 to 40 mg, due in large part to presystemic metabolism.
Projected row 1132
- Medicine slug
- omeprazole
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 280
- Source count
- 135
- Agreement rate
- 1
- Recorded readings
0.5 to 1 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 135
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 135 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a09ce48-7139-4fc7-9b6e-439459c8e866 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4ecc1e-5180-f75e-e063-6394a90a51a6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b83329ac-a65e-b3af-a3fb-c5a6c740e5e7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72fb11b6-b08c-2f02-d82b-f60f52394903 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b379ef-7982-434d-9e6b-e01cd2b398d2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f77efc97-2565-38ab-e053-6394a90aebda (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40f66cac-bc23-43f9-9966-87cce458c996 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a17e415e-a559-4a8d-a455-699184a01523 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b19d724-821b-61dc-e063-6294a90aa4d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d6e07d1-38b1-f2ab-e063-6294a90a34ac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17ccdbe0-19c1-498d-8e81-578be549b4e5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205652e1-7fbc-4b6a-bbd6-2fd346d812df (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f5502a-2e63-4f2a-a3ba-ddc5bd403051 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8bf92c9-1bab-7985-e053-2995a90a0225 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:516170d4-4913-4577-a2d2-f5c52d1e79c6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c311c1b9-8ec2-4ac0-baa2-a5063fba2d80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44349466-73ea-4053-8ff6-5b4b7372c9cd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1318a1c1-222d-471a-92d6-3632c82fb999 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b129fe93-c8a2-4ae8-ad1b-8f9ae5779b68 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a656a059-2b1a-44b3-85f8-af278032b54c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9724601b-bb12-4eb2-bc2e-0532976bf5d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9378c870-f2cc-4a60-b0fd-08a4d43857bc (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85afda-6b0c-d657-e053-2a95a90afb4b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1a6f05-ae3e-4f29-bc2d-8e9f51e5fe3e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded71262-d17f-3799-e053-2995a90a5427 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:603d2d06-c5e8-4378-a422-8dca1a410af7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ea9a6f3-b756-4cdf-b3db-f666a2c17d66 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61eab342-61fd-471f-8f70-95f9cbca0097 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3724b8f7-52ff-a5f8-e063-6294a90acf20 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa8fc2ea-3942-453b-bc19-1e4b14ba6926 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb34cff-59c5-4411-b587-10207ffb58c4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f13fd38-dc73-4072-bdc9-9474704a4121 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d99b4fd-49b3-403d-96a4-0cceda85a95c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ef8d55f-6cae-4b58-844b-968d8e5b8c24 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afda9d2c-b141-4c32-a5b4-e850974b30a3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dcf0b2-4fa2-023a-e053-2995a90a183a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dd5d63-1376-1ff7-e053-2a95a90a1d94 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df1a4294-3893-4a11-b4d5-f3536678087e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8090d4c3-3184-7812-53d7-aa30e14b79d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db9f071b-85f4-061f-e053-2995a90a3ff5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a19ce586-59b7-4c2e-9e8d-12e8f0f058e2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:062800b1-790a-41c3-a8be-94143d2c7fb6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30955530-56d2-174d-e063-6294a90a413c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d8be3f-ba13-4897-9ceb-f8ac6ccc1624 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:581d1c3d-457a-41f2-8db0-5b6219cdcb09 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1e0c8fc-1f15-45a4-a80f-653a1dae5e56 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e5d1b21-6b32-0c8d-e063-6294a90a8431 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665e9877-85ac-fdb6-54ac-1c47941ceab8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38bd8e13-591e-f11b-7d8a-11717c56493c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76c23d5-26b6-cfb2-e053-6294a90aea42 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63b3982a-b541-4b0d-99d4-93a673e57d46 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07af8c9-559c-5a93-e053-2a95a90a2c63 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:319d990e-161b-4c16-b026-f55c413c7e8f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ac077f-3873-4087-96d0-89049161dea9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96104ea6-c08f-40b5-83f5-d840b317f1fd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fa6afcf-33b3-3115-e053-2a91aa0abd0b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b1c61b-d4fe-433d-ad31-0b11758976fa (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed9895ae-3d18-434c-8b56-47bccdc8fe6d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50115204-74f7-17c1-e063-6394a90ab665 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b3918c-a66e-4277-8b8f-b7ece93fa7db (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa0395a7-4353-4d64-9de8-d15857a7031c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:530a8a66-48ad-474f-b170-c6fac95753ec (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:064b1418-0f42-4b18-9dee-cda40c5e1fca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0dc4ffa-db18-4871-9d36-51d02e3b2bd9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fc5065c-5850-469b-b357-fa4df30a8f78 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9786b04f-f827-460b-91bc-c0ac967f95dd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe7d3352-d53f-4046-92ed-1eb5c917fbee (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1249c42d-6358-48b3-8fe0-10333c7f501d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f873dc20-c817-5e4f-e053-6394a90a04f2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1276463-7357-45b5-9f7e-8d3c4a550ff4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb57c13-25ed-70bc-e063-6294a90afdac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40a75dc7-49b7-5c9d-6c5f-d4682ec6922e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40b4e1b6-f64d-44d5-bfc2-0cb8f78d9e67 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bda70ae-c3f6-450b-892f-6814795dd6ca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8991d464-7abc-4350-e053-2995a90a4ea7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92201fb1-4570-42db-8da3-3b8c0e291d32 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22ceb2-2c34-43c3-9a35-2589c9078741 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4562da8-9d94-4417-9f80-c1ffd4247259 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1f20429-cfaa-420b-a65a-271be37eb799 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a53ea447-add5-4ed5-aa7e-975b13d90e75 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7491dd-19f5-42e0-b901-7ba71a3820c7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0f61a89-700d-481d-9255-6f9a9afa7025 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85e324-ef9f-196c-e053-2995a90a384e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdc6809-3b1b-046a-e063-6394a90ae02a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd71fd8-3f36-46a1-bc76-53f6820d42a2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a9baece-03be-6c77-e063-6394a90a7032 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6c22be1-659d-4e71-b292-701e27da201b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcaadc8c-32d1-476f-b821-973c012b7fa7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded0df8b-1813-4595-ac2b-5499704bfd48 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c6e00a2-31e8-4e84-928d-80e69a5fc634 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aae3bf9f-5d05-889f-e053-2995a90a5ff2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e99b78b-7fb8-4514-a3db-58e59cd429d8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18f5a7cc-40d8-4aeb-a601-47bc9024f130 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39e3b45a-8e9b-49d6-976a-6668f4e27649 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:934601b6-fbba-43c4-a8ef-7a7dfe9f9a51 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:487ff32f-943e-458b-b898-bd7b0290cc49 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee0598a1-0e5e-40ff-ad88-b0adfc533ca0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb314cb-6291-422c-98ff-24d8449992f6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557d4c2c-5541-3a51-e063-6394a90ad278 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c41bcfa-b08b-3ac3-e053-2a95a90ae1c0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0344268f-d8e6-48d5-b1e1-f750ed1d8a52 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27b3518-d5c1-1229-e053-2a95a90ab56f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af707c0a-5193-3f83-e053-2995a90a78ef (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a806da8c-5f84-454d-966c-da1c48710f80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8f2e604-74fa-4205-b41f-32401e2dc59e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5564c9dc-6f99-6639-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad675ef6-5377-b9f2-e053-2995a90a06e9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be616c4-1b9a-5654-e054-00144ff88e88 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a1fb3c-f040-2e39-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4cd8ed1-d9d3-5b57-e053-2995a90a9f3c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f226173f-4318-43e0-847a-8ea237e6b41d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28515ff8-379d-5356-e063-6394a90af3f3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab3d84c-c563-6f04-e063-6394a90a34ff (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43090803-37de-77e3-e063-6294a90a8c43 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd1acb8-12dc-70b7-e063-6394a90a0399 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a3fbc9-00c6-ad83-e063-6294a90ae1ad (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288bdd5e-a0ac-4c5c-abe0-93183a28dcdd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3038133-8bb2-044e-e053-2995a90a6e7d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f5c91e6-6377-ca94-e063-6294a90a2f99 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0cf466-f9e8-390e-e063-6294a90a2ed8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dcd48e4-9ffc-9cc2-e063-6294a90ae17e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30e58465-c5d2-4925-85bb-53faa6135c5c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ad413ed-a21b-4f8b-9322-8fbb813b14d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17664f71-154a-47c6-b83c-b349bbc8a98f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b188d97-f1b3-468d-9818-b8333bf24b5a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500-600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c99e189-93c0-4461-82c2-4521e6c4d514 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d925ca6-83f1-4263-8218-4bf7cc8ceb39 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:253451a6-02a9-4b27-aed7-f3dbc2e09682 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e87d2206-9c06-438c-947b-10b29a879d7b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bab55f83-ba03-49a0-842a-19c9976b7fe8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e235ef89-3592-4ca1-8c13-d7ce84b1001c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4720cc17-013e-074e-e063-6294a90ac1f4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f6ad19-ff6a-7cd3-e053-6294a90ae1bf (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5af5f4b-17be-7245-b281-f27c87831242 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9359e826-5263-44fc-8dd3-9d0852fe42d6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500 to 600 mL/min.
Projected row 1133
- Medicine slug
- omeprazole
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 280
- Source count
- 135
- Agreement rate
- 1
- Recorded readings
95%
- Numeric value
- 95
- Unit
- %
- Source records
- 135
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 135 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a09ce48-7139-4fc7-9b6e-439459c8e866 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4ecc1e-5180-f75e-e063-6394a90a51a6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b83329ac-a65e-b3af-a3fb-c5a6c740e5e7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72fb11b6-b08c-2f02-d82b-f60f52394903 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b379ef-7982-434d-9e6b-e01cd2b398d2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f77efc97-2565-38ab-e053-6394a90aebda (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40f66cac-bc23-43f9-9966-87cce458c996 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a17e415e-a559-4a8d-a455-699184a01523 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b19d724-821b-61dc-e063-6294a90aa4d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d6e07d1-38b1-f2ab-e063-6294a90a34ac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17ccdbe0-19c1-498d-8e81-578be549b4e5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205652e1-7fbc-4b6a-bbd6-2fd346d812df (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f5502a-2e63-4f2a-a3ba-ddc5bd403051 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8bf92c9-1bab-7985-e053-2995a90a0225 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:516170d4-4913-4577-a2d2-f5c52d1e79c6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c311c1b9-8ec2-4ac0-baa2-a5063fba2d80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44349466-73ea-4053-8ff6-5b4b7372c9cd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1318a1c1-222d-471a-92d6-3632c82fb999 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b129fe93-c8a2-4ae8-ad1b-8f9ae5779b68 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a656a059-2b1a-44b3-85f8-af278032b54c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9724601b-bb12-4eb2-bc2e-0532976bf5d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9378c870-f2cc-4a60-b0fd-08a4d43857bc (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85afda-6b0c-d657-e053-2a95a90afb4b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1a6f05-ae3e-4f29-bc2d-8e9f51e5fe3e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded71262-d17f-3799-e053-2995a90a5427 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:603d2d06-c5e8-4378-a422-8dca1a410af7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ea9a6f3-b756-4cdf-b3db-f666a2c17d66 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61eab342-61fd-471f-8f70-95f9cbca0097 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3724b8f7-52ff-a5f8-e063-6294a90acf20 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa8fc2ea-3942-453b-bc19-1e4b14ba6926 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb34cff-59c5-4411-b587-10207ffb58c4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f13fd38-dc73-4072-bdc9-9474704a4121 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d99b4fd-49b3-403d-96a4-0cceda85a95c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ef8d55f-6cae-4b58-844b-968d8e5b8c24 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afda9d2c-b141-4c32-a5b4-e850974b30a3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dcf0b2-4fa2-023a-e053-2995a90a183a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dd5d63-1376-1ff7-e053-2a95a90a1d94 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df1a4294-3893-4a11-b4d5-f3536678087e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8090d4c3-3184-7812-53d7-aa30e14b79d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db9f071b-85f4-061f-e053-2995a90a3ff5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a19ce586-59b7-4c2e-9e8d-12e8f0f058e2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:062800b1-790a-41c3-a8be-94143d2c7fb6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30955530-56d2-174d-e063-6294a90a413c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d8be3f-ba13-4897-9ceb-f8ac6ccc1624 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:581d1c3d-457a-41f2-8db0-5b6219cdcb09 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1e0c8fc-1f15-45a4-a80f-653a1dae5e56 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e5d1b21-6b32-0c8d-e063-6294a90a8431 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665e9877-85ac-fdb6-54ac-1c47941ceab8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38bd8e13-591e-f11b-7d8a-11717c56493c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76c23d5-26b6-cfb2-e053-6294a90aea42 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63b3982a-b541-4b0d-99d4-93a673e57d46 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07af8c9-559c-5a93-e053-2a95a90a2c63 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:319d990e-161b-4c16-b026-f55c413c7e8f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ac077f-3873-4087-96d0-89049161dea9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96104ea6-c08f-40b5-83f5-d840b317f1fd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fa6afcf-33b3-3115-e053-2a91aa0abd0b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b1c61b-d4fe-433d-ad31-0b11758976fa (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed9895ae-3d18-434c-8b56-47bccdc8fe6d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50115204-74f7-17c1-e063-6394a90ab665 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b3918c-a66e-4277-8b8f-b7ece93fa7db (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa0395a7-4353-4d64-9de8-d15857a7031c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:530a8a66-48ad-474f-b170-c6fac95753ec (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:064b1418-0f42-4b18-9dee-cda40c5e1fca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0dc4ffa-db18-4871-9d36-51d02e3b2bd9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fc5065c-5850-469b-b357-fa4df30a8f78 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9786b04f-f827-460b-91bc-c0ac967f95dd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe7d3352-d53f-4046-92ed-1eb5c917fbee (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1249c42d-6358-48b3-8fe0-10333c7f501d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f873dc20-c817-5e4f-e053-6394a90a04f2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1276463-7357-45b5-9f7e-8d3c4a550ff4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb57c13-25ed-70bc-e063-6294a90afdac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40a75dc7-49b7-5c9d-6c5f-d4682ec6922e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40b4e1b6-f64d-44d5-bfc2-0cb8f78d9e67 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bda70ae-c3f6-450b-892f-6814795dd6ca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8991d464-7abc-4350-e053-2995a90a4ea7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92201fb1-4570-42db-8da3-3b8c0e291d32 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22ceb2-2c34-43c3-9a35-2589c9078741 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4562da8-9d94-4417-9f80-c1ffd4247259 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1f20429-cfaa-420b-a65a-271be37eb799 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a53ea447-add5-4ed5-aa7e-975b13d90e75 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7491dd-19f5-42e0-b901-7ba71a3820c7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0f61a89-700d-481d-9255-6f9a9afa7025 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85e324-ef9f-196c-e053-2995a90a384e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdc6809-3b1b-046a-e063-6394a90ae02a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd71fd8-3f36-46a1-bc76-53f6820d42a2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a9baece-03be-6c77-e063-6394a90a7032 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6c22be1-659d-4e71-b292-701e27da201b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcaadc8c-32d1-476f-b821-973c012b7fa7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded0df8b-1813-4595-ac2b-5499704bfd48 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c6e00a2-31e8-4e84-928d-80e69a5fc634 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aae3bf9f-5d05-889f-e053-2995a90a5ff2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e99b78b-7fb8-4514-a3db-58e59cd429d8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18f5a7cc-40d8-4aeb-a601-47bc9024f130 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39e3b45a-8e9b-49d6-976a-6668f4e27649 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:934601b6-fbba-43c4-a8ef-7a7dfe9f9a51 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:487ff32f-943e-458b-b898-bd7b0290cc49 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee0598a1-0e5e-40ff-ad88-b0adfc533ca0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb314cb-6291-422c-98ff-24d8449992f6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557d4c2c-5541-3a51-e063-6394a90ad278 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c41bcfa-b08b-3ac3-e053-2a95a90ae1c0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0344268f-d8e6-48d5-b1e1-f750ed1d8a52 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27b3518-d5c1-1229-e053-2a95a90ab56f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af707c0a-5193-3f83-e053-2995a90a78ef (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a806da8c-5f84-454d-966c-da1c48710f80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8f2e604-74fa-4205-b41f-32401e2dc59e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5564c9dc-6f99-6639-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad675ef6-5377-b9f2-e053-2995a90a06e9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be616c4-1b9a-5654-e054-00144ff88e88 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a1fb3c-f040-2e39-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4cd8ed1-d9d3-5b57-e053-2995a90a9f3c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f226173f-4318-43e0-847a-8ea237e6b41d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28515ff8-379d-5356-e063-6394a90af3f3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab3d84c-c563-6f04-e063-6394a90a34ff (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43090803-37de-77e3-e063-6294a90a8c43 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd1acb8-12dc-70b7-e063-6394a90a0399 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a3fbc9-00c6-ad83-e063-6294a90ae1ad (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288bdd5e-a0ac-4c5c-abe0-93183a28dcdd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3038133-8bb2-044e-e053-2995a90a6e7d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f5c91e6-6377-ca94-e063-6294a90a2f99 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0cf466-f9e8-390e-e063-6294a90a2ed8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dcd48e4-9ffc-9cc2-e063-6294a90ae17e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30e58465-c5d2-4925-85bb-53faa6135c5c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ad413ed-a21b-4f8b-9322-8fbb813b14d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17664f71-154a-47c6-b83c-b349bbc8a98f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b188d97-f1b3-468d-9818-b8333bf24b5a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c99e189-93c0-4461-82c2-4521e6c4d514 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d925ca6-83f1-4263-8218-4bf7cc8ceb39 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:253451a6-02a9-4b27-aed7-f3dbc2e09682 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e87d2206-9c06-438c-947b-10b29a879d7b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bab55f83-ba03-49a0-842a-19c9976b7fe8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e235ef89-3592-4ca1-8c13-d7ce84b1001c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4720cc17-013e-074e-e063-6294a90ac1f4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f6ad19-ff6a-7cd3-e053-6294a90ae1bf (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5af5f4b-17be-7245-b281-f27c87831242 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9359e826-5263-44fc-8dd3-9d0852fe42d6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Distribution Protein binding is approximately 95%.
Projected row 1134
- Medicine slug
- omeprazole
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 280
- Source count
- 130
- Agreement rate
- 1
- Recorded readings
0.5 to 3.5 hours
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 130
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 130 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a09ce48-7139-4fc7-9b6e-439459c8e866 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4ecc1e-5180-f75e-e063-6394a90a51a6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b83329ac-a65e-b3af-a3fb-c5a6c740e5e7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72fb11b6-b08c-2f02-d82b-f60f52394903 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b379ef-7982-434d-9e6b-e01cd2b398d2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f77efc97-2565-38ab-e053-6394a90aebda (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40f66cac-bc23-43f9-9966-87cce458c996 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a17e415e-a559-4a8d-a455-699184a01523 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b19d724-821b-61dc-e063-6294a90aa4d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d6e07d1-38b1-f2ab-e063-6294a90a34ac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17ccdbe0-19c1-498d-8e81-578be549b4e5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205652e1-7fbc-4b6a-bbd6-2fd346d812df (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f5502a-2e63-4f2a-a3ba-ddc5bd403051 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8bf92c9-1bab-7985-e053-2995a90a0225 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:516170d4-4913-4577-a2d2-f5c52d1e79c6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c311c1b9-8ec2-4ac0-baa2-a5063fba2d80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44349466-73ea-4053-8ff6-5b4b7372c9cd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1318a1c1-222d-471a-92d6-3632c82fb999 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b129fe93-c8a2-4ae8-ad1b-8f9ae5779b68 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a656a059-2b1a-44b3-85f8-af278032b54c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9724601b-bb12-4eb2-bc2e-0532976bf5d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9378c870-f2cc-4a60-b0fd-08a4d43857bc (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85afda-6b0c-d657-e053-2a95a90afb4b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1a6f05-ae3e-4f29-bc2d-8e9f51e5fe3e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded71262-d17f-3799-e053-2995a90a5427 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:603d2d06-c5e8-4378-a422-8dca1a410af7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ea9a6f3-b756-4cdf-b3db-f666a2c17d66 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61eab342-61fd-471f-8f70-95f9cbca0097 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3724b8f7-52ff-a5f8-e063-6294a90acf20 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa8fc2ea-3942-453b-bc19-1e4b14ba6926 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb34cff-59c5-4411-b587-10207ffb58c4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f13fd38-dc73-4072-bdc9-9474704a4121 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d99b4fd-49b3-403d-96a4-0cceda85a95c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ef8d55f-6cae-4b58-844b-968d8e5b8c24 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afda9d2c-b141-4c32-a5b4-e850974b30a3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dcf0b2-4fa2-023a-e053-2995a90a183a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5dd5d63-1376-1ff7-e053-2a95a90a1d94 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df1a4294-3893-4a11-b4d5-f3536678087e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8090d4c3-3184-7812-53d7-aa30e14b79d1 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db9f071b-85f4-061f-e053-2995a90a3ff5 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a19ce586-59b7-4c2e-9e8d-12e8f0f058e2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:062800b1-790a-41c3-a8be-94143d2c7fb6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30955530-56d2-174d-e063-6294a90a413c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d8be3f-ba13-4897-9ceb-f8ac6ccc1624 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:581d1c3d-457a-41f2-8db0-5b6219cdcb09 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1e0c8fc-1f15-45a4-a80f-653a1dae5e56 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e5d1b21-6b32-0c8d-e063-6294a90a8431 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665e9877-85ac-fdb6-54ac-1c47941ceab8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38bd8e13-591e-f11b-7d8a-11717c56493c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76c23d5-26b6-cfb2-e053-6294a90aea42 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63b3982a-b541-4b0d-99d4-93a673e57d46 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07af8c9-559c-5a93-e053-2a95a90a2c63 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:319d990e-161b-4c16-b026-f55c413c7e8f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96104ea6-c08f-40b5-83f5-d840b317f1fd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fa6afcf-33b3-3115-e053-2a91aa0abd0b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b1c61b-d4fe-433d-ad31-0b11758976fa (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed9895ae-3d18-434c-8b56-47bccdc8fe6d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50115204-74f7-17c1-e063-6394a90ab665 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b3918c-a66e-4277-8b8f-b7ece93fa7db (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa0395a7-4353-4d64-9de8-d15857a7031c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:530a8a66-48ad-474f-b170-c6fac95753ec (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:064b1418-0f42-4b18-9dee-cda40c5e1fca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0dc4ffa-db18-4871-9d36-51d02e3b2bd9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fc5065c-5850-469b-b357-fa4df30a8f78 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9786b04f-f827-460b-91bc-c0ac967f95dd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe7d3352-d53f-4046-92ed-1eb5c917fbee (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1249c42d-6358-48b3-8fe0-10333c7f501d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f873dc20-c817-5e4f-e053-6394a90a04f2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1276463-7357-45b5-9f7e-8d3c4a550ff4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb57c13-25ed-70bc-e063-6294a90afdac (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40a75dc7-49b7-5c9d-6c5f-d4682ec6922e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40b4e1b6-f64d-44d5-bfc2-0cb8f78d9e67 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bda70ae-c3f6-450b-892f-6814795dd6ca (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8991d464-7abc-4350-e053-2995a90a4ea7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92201fb1-4570-42db-8da3-3b8c0e291d32 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22ceb2-2c34-43c3-9a35-2589c9078741 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4562da8-9d94-4417-9f80-c1ffd4247259 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1f20429-cfaa-420b-a65a-271be37eb799 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a53ea447-add5-4ed5-aa7e-975b13d90e75 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7491dd-19f5-42e0-b901-7ba71a3820c7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af85e324-ef9f-196c-e053-2995a90a384e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdc6809-3b1b-046a-e063-6394a90ae02a (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd71fd8-3f36-46a1-bc76-53f6820d42a2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a9baece-03be-6c77-e063-6394a90a7032 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6c22be1-659d-4e71-b292-701e27da201b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcaadc8c-32d1-476f-b821-973c012b7fa7 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ded0df8b-1813-4595-ac2b-5499704bfd48 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c6e00a2-31e8-4e84-928d-80e69a5fc634 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aae3bf9f-5d05-889f-e053-2995a90a5ff2 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e99b78b-7fb8-4514-a3db-58e59cd429d8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18f5a7cc-40d8-4aeb-a601-47bc9024f130 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39e3b45a-8e9b-49d6-976a-6668f4e27649 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:934601b6-fbba-43c4-a8ef-7a7dfe9f9a51 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:487ff32f-943e-458b-b898-bd7b0290cc49 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee0598a1-0e5e-40ff-ad88-b0adfc533ca0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb314cb-6291-422c-98ff-24d8449992f6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:557d4c2c-5541-3a51-e063-6394a90ad278 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c41bcfa-b08b-3ac3-e053-2a95a90ae1c0 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0344268f-d8e6-48d5-b1e1-f750ed1d8a52 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27b3518-d5c1-1229-e053-2a95a90ab56f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af707c0a-5193-3f83-e053-2995a90a78ef (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a806da8c-5f84-454d-966c-da1c48710f80 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8f2e604-74fa-4205-b41f-32401e2dc59e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5564c9dc-6f99-6639-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad675ef6-5377-b9f2-e053-2995a90a06e9 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be616c4-1b9a-5654-e054-00144ff88e88 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a1fb3c-f040-2e39-e054-00144ff8d46c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4cd8ed1-d9d3-5b57-e053-2995a90a9f3c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f226173f-4318-43e0-847a-8ea237e6b41d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28515ff8-379d-5356-e063-6394a90af3f3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab3d84c-c563-6f04-e063-6394a90a34ff (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43090803-37de-77e3-e063-6294a90a8c43 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd1acb8-12dc-70b7-e063-6394a90a0399 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a3fbc9-00c6-ad83-e063-6294a90ae1ad (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288bdd5e-a0ac-4c5c-abe0-93183a28dcdd (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3038133-8bb2-044e-e053-2995a90a6e7d (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f5c91e6-6377-ca94-e063-6294a90a2f99 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0cf466-f9e8-390e-e063-6294a90a2ed8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dcd48e4-9ffc-9cc2-e063-6294a90ae17e (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30e58465-c5d2-4925-85bb-53faa6135c5c (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ad413ed-a21b-4f8b-9322-8fbb813b14d3 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17664f71-154a-47c6-b83c-b349bbc8a98f (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c99e189-93c0-4461-82c2-4521e6c4d514 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d925ca6-83f1-4263-8218-4bf7cc8ceb39 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e87d2206-9c06-438c-947b-10b29a879d7b (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bab55f83-ba03-49a0-842a-19c9976b7fe8 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4720cc17-013e-074e-e063-6294a90ac1f4 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f6ad19-ff6a-7cd3-e053-6294a90ae1bf (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5af5f4b-17be-7245-b281-f27c87831242 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9359e826-5263-44fc-8dd3-9d0852fe42d6 (opens source in a new tab)
Omeprazole label
Version not recorded · Effective date not recorded
Absorption is rapid, with peak plasma concentrations of omeprazole occurring within 0.5 to 3.5 hours.
Projected row 1135
- Medicine slug
- ondansetron
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 223
- Source count
- 195
- Agreement rate
- 0.8
- Recorded readings
11.6 hours
- Numeric value
- 11.6
- Unit
- hours
- Source records
- 156
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 156 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e436e361-da0f-7d6d-e053-2995a90a10e4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2e8efe-7fd4-407c-a77b-bd6dd04608e2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c83821ad-822e-47dc-8108-612312cf3a16 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47e26779-9465-410c-96b3-091119ae62f2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87fd7e8e-fd04-34ad-e053-2a95a90a236d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8585e68b-965f-4f95-a5df-eea023cd5f82 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54e8981e-6880-4d4f-bc46-600c2af59698 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e183c59c-2a7c-dba3-e053-2a95a90acf87 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9abd5ce-6aca-4fda-8f46-0bb5b7fdd5da (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fa30bdb-f60e-40a7-98b4-c346bc85d539 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2086bae8-7c3c-4663-93ac-c86407c524c2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90b73778-2ab5-5460-e053-2a95a90abbc1 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4dcd1e4c-6a9c-7ac6-e063-6394a90a39bf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cc67d95-6629-4451-9e34-2f7a60482be5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:541b9a0d-ae94-db6f-e063-6394a90a9805 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70b48280-ef74-472b-abc3-128962bfcb05 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb74425c-c635-4d99-8e98-e63e7359fb89 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:115e8fb5-61f5-4719-8eb3-063b7ca194ae (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9321ef6-9fe5-4631-9c58-534fd963cf17 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8f371c7-09f8-426c-ae22-753cd5626da3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:674ea285-8f84-4603-9655-82200c523fe5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af75407e-82aa-136f-e053-2995a90a429b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a79fc2b-9ea3-a808-e063-6394a90ae794 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76d27c5-acd4-482c-e053-6294a90a5284 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29f8ae1-4826-d8eb-e053-2a95a90a691a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07c38c0-e1c2-01de-e053-2995a90a390a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00b17a8e-9d38-a8d4-e063-6294a90a153e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee3e8cbe-4f0b-4361-a1b5-8329d85a2932 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b38feff2-900a-4e0c-8260-8f090edbc0bc (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d696b8c-eba6-505e-e053-2995a90acb5d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f2e4ee-dc8b-478d-b0d6-d192119691b7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1191e52-982e-49d1-946e-01b469ccedfe (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41c0dc3d-a616-425e-9073-625a0cb692c4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd09b19b-3b7b-474a-9c88-98b813d2c53b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e289184-6046-4b55-97d2-cb276d5782d5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f315229-7e8f-67fd-e053-2a91aa0a8cb6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91bfbc0e-86a3-8ac6-e053-2a95a90af432 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1dd7420-dd81-2c8e-e053-2995a90ac8e6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2553816f-161e-ac86-e063-6394a90aad6d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af836a30-5e51-5c97-e053-2995a90a15b9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ada0e4-5c1b-17ab-e053-6294a90a12b8 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40106070-6a25-5b0e-e063-6394a90a4197 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b502e2-03ed-fe5c-e053-2995a90a368e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77397df5-5a4f-41b2-98bc-f817a1e497fc (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a14eb9a-0385-40e9-a7ec-71435450ac91 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2edc0788-dc38-4d21-ba8e-71f159e2d3b1 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:162f2088-9fb1-47e7-b88c-45104be7e7bb (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a76bae2-04c2-ee2d-e063-6394a90ad4c8 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cab63f24-8728-4927-aba5-53e8d2e44cdb (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a0b9ee-c1d2-7818-e053-2995a90a3e96 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:269c920c-643a-4eea-9bf9-b1f008915db9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69ed01b7-a94e-4946-a044-a9f8c37616ec (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a22a94bc-4fa7-8a4e-e053-2a95a90a6308 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59c817b7-a1c6-48a5-9bfc-2c381532bfd9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad92ffb6-dc63-48dc-9fcc-37fd3d42a75c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00327696-c496-4c83-a63e-9e29fd6246d4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e0b1b09-9e68-4728-82d5-1f86510a0f2a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a863485-a0a8-db63-e063-6294a90ab605 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af830edc-ce9e-b038-e053-2a95a90ae974 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:281e4296-1d0e-4602-9912-2685ba1640f6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:426ba54f-199a-41d1-8c27-f827bea56854 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36d64400-2d13-4a1a-a1ca-4741cd3d3f1a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d5e7650-95be-4b96-b29c-374f673eb7a1 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c66d63cf-a0e5-4cb5-bdf8-9d1115cba23e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0f69f57-aeb9-4890-85aa-e5976208e8be (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68a4d845-0c1c-4867-bfca-c0fb11dc93cd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment : In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546191d2-d092-6342-e063-6294a90a0cd3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:384a5cfb-05dd-2b79-73f4-a01a47a9eb3e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a29b5c18-9884-4c88-8827-65d9ad5f69f6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10afd68b-877f-4819-a314-39f2d56d5db9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08db5ce7-4dcf-4581-a0bf-f405cc22b48d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aeb533a-e72c-4af8-9867-b71d2eba9a49 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b062fa9-e004-23d5-e053-2a91aa0a20cd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43e15d6-b778-7575-e053-2995a90a93a0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26aff90c-49ea-46ac-bbf3-c188c2b061c9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40258e4b-5e67-46c0-8ef0-3e8bfe36ba11 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65b0b2e2-37fd-4d08-9674-954d62bb531a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3207cf04-73b7-24ce-e054-00144ff8d46c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14276805-4e99-4bbe-ad76-ffc06eddb38a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ab3210e-eed1-479a-afc0-f72b5b776883 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a30d534-4607-4882-865e-56d2364acaad (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a0c4dc6-643e-4ee7-92a9-edb98049a5ba (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee668456-a214-4452-ab9d-ec00eaa41d79 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5ab38a2-5921-4320-a313-e0080c078046 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4feb4b89-2d2f-4a9c-a4f4-5ae3e26281b6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e41b9469-e844-47d9-933a-4c9f4453ecc7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:476e704c-95ae-4591-94f7-ee4ab827ff13 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67395789-0ac7-2244-e053-2a91aa0a652a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8d775b6-478c-499e-82be-bfdf006445e3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89091629-d15e-4e95-aed8-8bc983c78302 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04800a86-2391-44e6-8763-d65e8a916c26 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72f29916-0f95-102d-e053-2991aa0aa5cd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57578387-1918-4e56-a564-f14fb22340bf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9558d296-8edd-4aa1-875a-6247f9a8374d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960e2104-18c3-4cfa-abf6-f1b30c452918 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:416be720-82e8-4a6d-8531-c1a29869daae (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:852a3251-bf28-5557-e053-2991aa0a4fbd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1324076-f83e-4816-9e02-6b2a689010bc (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb02f2d7-31a9-4f12-880e-7ce7d85440d4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:561dce26-92fa-e00b-e063-6294a90a1ab2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b7432b-f5a7-40f3-9b0c-e7b125f5103c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b50c1767-8a50-49ab-be31-6533021ae7c4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6694136-7591-4f23-8415-f2aa3c8bab40 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:834bc56a-657d-4733-9a60-47040cb5c7bf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65f01335-452e-42c6-a59b-4eb03badc55a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9913ed0c-aaad-45e1-b522-98ad170c2e8a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251d7b9a-f935-42f7-b985-91b8bba7637b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d1b8953-7ff5-4e91-ba97-3ba5c6ea8f71 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f08f56de-8678-4da9-8cae-013a5c393453 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac3dfb81-a4c7-4147-9374-c234153b7c51 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e862601-1d8a-455b-8ce5-1a32478b309f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9ea1fc-59a4-8189-e063-6394a90a9ae6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment : In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2c0e86c-e7fc-48f9-a894-02da8761001c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f015e60-1aec-4ae7-b28f-42f6c8f50455 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66ac9c17-bea7-4f8d-8a27-a1e0f9e65945 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c758a3-e749-4a15-be4b-ee30b364b2b0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37de0550-a6d1-46a8-a0b8-447b0dcf70ad (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0be25a0-e13d-4242-93dc-0b86e82aadd7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db9a0d22-9339-4319-e053-2a95a90a9592 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dff6676-e69e-779d-e053-2995a90a7c81 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e24f935-87fe-4b6a-b265-60b1039f38d5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbe71308-2927-2467-e053-6394a90aa419 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b297c163-2052-cb22-e053-2995a90a8289 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:381b44e7-a5a1-42ad-bcea-1ab4c82ff5d4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bde7c22c-0047-4735-8df6-b48e8dfa478a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cd0c27-788d-5fd8-e053-2a91aa0a7c69 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b406d22-f1bf-460d-e063-6294a90a6b6f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4766235-ac44-ca93-78a6-66d4ded33ada (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2eeb3c61-4ce9-d8ed-e063-6294a90a00d3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38435346-d505-4bdd-bbc6-a7bcba411033 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76666e7e-3312-6f9d-e053-2991aa0af705 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:378d0963-d026-4478-8202-fbb636904a37 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db99c77a-0b01-9da6-e053-2a95a90a5199 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b96072-e8f2-4fd6-aaa0-b73fed214319 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b0a1e5-5dfa-64a0-e063-6394a90acf36 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:822404ad-af08-4c62-ae38-7d9819e86079 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7949c245-b79f-4eaf-a75f-9a17bd7bd307 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f9fc8a2-0cfd-12f1-e053-2995a90acf3d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e0e508-75f7-4c8b-bb38-898aa4c531c3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c74336c-11ec-420a-80e1-d8e4a8f1c46d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81366c85-c6c9-4a9a-9fe5-cdd8c2d19f74 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cf8d4f-ac57-4177-e063-6394a90ae804 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b76c5cc9-f1ca-428b-8989-36a66802b650 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c4cda2f-13d9-42c5-b449-77deb06c8de5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5566aebb-d84d-6d6a-e063-6294a90a746f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64527de5-0b92-4340-9243-7a37e8ff96d9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment : In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af735f22-6d6c-6e1f-e053-2a95a90a3532 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d71d26-0d42-b368-e063-6394a90add43 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf10d256-dd89-4a91-a3ed-81db505a79c2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84234d20-aa73-446f-9a1b-846e0cb80cec (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b675b09-fe40-435c-b91a-c61cdf767fbf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dafe875e-391f-47a2-97b7-89840a760e44 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36592150-7e19-474c-9f96-cc8341e28b5d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment : In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58f16a00-3e66-29de-e053-2991aa0a59a0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18063a64-a4c0-4bad-911b-00df5c7bb65d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in healthy subjects.
4.0 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 37
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 37 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d5d25eb-8711-ef8c-e063-6394a90a5e03 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c68d202-fdf7-4b6a-dd7f-82624fcdbd4a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f22b7e-b6ad-4799-93c7-d30540cada85 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a11f61b-2318-4382-2b91-4366e4bb53fa (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97713356-f42b-4a67-95f6-561afa68c0c2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
E xcretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70bf93bc-e979-f080-e053-2991aa0a21df (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
E xcretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cea2f3a-cfa5-4a68-9ff4-b5a5a2085d08 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b746d4db-43e6-4219-9e6b-f53e59581305 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95ca0d81-a0a8-441d-820e-cb6624018a15 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d62cd60b-f87e-4825-bead-1d18bbc4e480 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de72f1ec-75dd-4659-a1a0-32b28b72c799 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99ac0a5e-dd2a-4352-e053-2a95a90a68fd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98c1413c-ff7f-4554-9e9f-289038b39ca6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5fe05bc-a7a5-4131-8c4d-2edd113441ec (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb4bc810-db26-471b-9ce7-6e2fb3018af0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9c2d9f-62a8-4d26-a041-a598bc59e300 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79756604-56e6-d0ef-e053-2991aa0adc99 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61758670-91ab-4422-8d9d-e8ca87eecae8 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b60074e5-8e77-4dc0-9244-4205e4adbaef (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70437694-0341-4f3b-824c-06843403443f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
E xcretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba0f8f13-1f7d-44e0-9c0f-0b43a9e8e3a7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3efa5604-96c3-42a0-8e99-b3de4a66aa92 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35e0d160-813f-41d7-a382-d2cab6485d9c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30107d6f-5128-484f-b713-65244a98dc67 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0050959-c14c-41b6-9a92-fadc5f6feff3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e09e262-dadf-4ae0-825e-448ea8dac174 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d89017aa-b8c3-4fd2-8e68-44e2cfd6f290 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a231919-6837-4b09-b66d-3706432b9702 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:438c3d28-8bed-50f0-e063-6394a90a18e4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0862c02-781f-4b10-ae50-9c9c4ca26f6d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a62e2a6a-6235-7580-e053-2a95a90aa2b0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee1f115f-c8f8-4526-b827-c8e48aeb5050 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35716914-ac73-43c0-9aa0-09c99211d941 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c29ca6df-621d-44b6-98fc-b48666573366 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
E xcretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:768aa02b-8231-5799-e053-2a91aa0a618d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89698ef8-62d3-77e4-e053-2995a90ab9db (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:729d865f-d84a-495e-9456-4bceebb6e03f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cc94c7a-617c-4238-8248-e3fabc9612c7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:993cd1d7-70a1-a431-e053-2a95a90a5771 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Elimination: In adult cancer patients, the mean ondansetron elimination half-life was 4 hours, and there was no difference in the multiple dose pharmacokinetics over a 4 day period.
Projected row 1136
- Medicine slug
- ondansetron
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 223
- Source count
- 222
- Agreement rate
- 1
- Recorded readings
70%
- Numeric value
- 70
- Unit
- %
- Source records
- 222
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 222 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e436e361-da0f-7d6d-e053-2995a90a10e4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2e8efe-7fd4-407c-a77b-bd6dd04608e2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c83821ad-822e-47dc-8108-612312cf3a16 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47e26779-9465-410c-96b3-091119ae62f2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87fd7e8e-fd04-34ad-e053-2a95a90a236d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8585e68b-965f-4f95-a5df-eea023cd5f82 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54e8981e-6880-4d4f-bc46-600c2af59698 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e183c59c-2a7c-dba3-e053-2a95a90acf87 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d5d25eb-8711-ef8c-e063-6394a90a5e03 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9abd5ce-6aca-4fda-8f46-0bb5b7fdd5da (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cc94c7a-617c-4238-8248-e3fabc9612c7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c68d202-fdf7-4b6a-dd7f-82624fcdbd4a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fa30bdb-f60e-40a7-98b4-c346bc85d539 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2086bae8-7c3c-4663-93ac-c86407c524c2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29f5cfa-3cc4-7d53-e053-2995a90ae844 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90b73778-2ab5-5460-e053-2a95a90abbc1 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f22b7e-b6ad-4799-93c7-d30540cada85 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4dcd1e4c-6a9c-7ac6-e063-6394a90a39bf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cc67d95-6629-4451-9e34-2f7a60482be5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a11f61b-2318-4382-2b91-4366e4bb53fa (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:541b9a0d-ae94-db6f-e063-6394a90a9805 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a44601b-c31c-4779-a688-28cc4cc75e8b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70b48280-ef74-472b-abc3-128962bfcb05 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb74425c-c635-4d99-8e98-e63e7359fb89 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97713356-f42b-4a67-95f6-561afa68c0c2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:115e8fb5-61f5-4719-8eb3-063b7ca194ae (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9321ef6-9fe5-4631-9c58-534fd963cf17 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:677b5fc5-9471-638b-e053-2991aa0a7f97 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70bf93bc-e979-f080-e053-2991aa0a21df (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8f371c7-09f8-426c-ae22-753cd5626da3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:674ea285-8f84-4603-9655-82200c523fe5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af75407e-82aa-136f-e053-2995a90a429b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a79fc2b-9ea3-a808-e063-6394a90ae794 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cea2f3a-cfa5-4a68-9ff4-b5a5a2085d08 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76d27c5-acd4-482c-e053-6294a90a5284 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29f8ae1-4826-d8eb-e053-2a95a90a691a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b746d4db-43e6-4219-9e6b-f53e59581305 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e07c38c0-e1c2-01de-e053-2995a90a390a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95ca0d81-a0a8-441d-820e-cb6624018a15 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d62cd60b-f87e-4825-bead-1d18bbc4e480 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de72f1ec-75dd-4659-a1a0-32b28b72c799 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352de988-d166-c2d8-e063-6294a90acc01 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00b17a8e-9d38-a8d4-e063-6294a90a153e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee3e8cbe-4f0b-4361-a1b5-8329d85a2932 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c34ca82-9705-4784-be7c-8b50351d14fc (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b38feff2-900a-4e0c-8260-8f090edbc0bc (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:300b1916-a3d8-0220-e063-6394a90a6f55 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d696b8c-eba6-505e-e053-2995a90acb5d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f2e4ee-dc8b-478d-b0d6-d192119691b7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1191e52-982e-49d1-946e-01b469ccedfe (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41c0dc3d-a616-425e-9073-625a0cb692c4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd09b19b-3b7b-474a-9c88-98b813d2c53b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e289184-6046-4b55-97d2-cb276d5782d5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f315229-7e8f-67fd-e053-2a91aa0a8cb6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91bfbc0e-86a3-8ac6-e053-2a95a90af432 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1dd7420-dd81-2c8e-e053-2995a90ac8e6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2553816f-161e-ac86-e063-6394a90aad6d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af836a30-5e51-5c97-e053-2995a90a15b9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a0ea2c-0788-4e8a-e053-2a95a90a2f32 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99ac0a5e-dd2a-4352-e053-2a95a90a68fd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ada0e4-5c1b-17ab-e053-6294a90a12b8 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40d9cc46-aced-4866-812b-7d82933596ae (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40106070-6a25-5b0e-e063-6394a90a4197 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b502e2-03ed-fe5c-e053-2995a90a368e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98c1413c-ff7f-4554-9e9f-289038b39ca6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77397df5-5a4f-41b2-98bc-f817a1e497fc (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a14eb9a-0385-40e9-a7ec-71435450ac91 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2edc0788-dc38-4d21-ba8e-71f159e2d3b1 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:162f2088-9fb1-47e7-b88c-45104be7e7bb (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a76bae2-04c2-ee2d-e063-6394a90ad4c8 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cab63f24-8728-4927-aba5-53e8d2e44cdb (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a0b9ee-c1d2-7818-e053-2995a90a3e96 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:269c920c-643a-4eea-9bf9-b1f008915db9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:993cd1d7-70a1-a431-e053-2a95a90a5771 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution: Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69ed01b7-a94e-4946-a044-a9f8c37616ec (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a22a94bc-4fa7-8a4e-e053-2a95a90a6308 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59c817b7-a1c6-48a5-9bfc-2c381532bfd9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad92ffb6-dc63-48dc-9fcc-37fd3d42a75c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00327696-c496-4c83-a63e-9e29fd6246d4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e0b1b09-9e68-4728-82d5-1f86510a0f2a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a863485-a0a8-db63-e063-6294a90ab605 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af830edc-ce9e-b038-e053-2a95a90ae974 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:281e4296-1d0e-4602-9912-2685ba1640f6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:426ba54f-199a-41d1-8c27-f827bea56854 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36d64400-2d13-4a1a-a1ca-4741cd3d3f1a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d5e7650-95be-4b96-b29c-374f673eb7a1 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c66d63cf-a0e5-4cb5-bdf8-9d1115cba23e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5fe05bc-a7a5-4131-8c4d-2edd113441ec (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0f69f57-aeb9-4890-85aa-e5976208e8be (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df736abd-9cec-4e90-e053-2995a90aab5e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb4bc810-db26-471b-9ce7-6e2fb3018af0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68a4d845-0c1c-4867-bfca-c0fb11dc93cd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546191d2-d092-6342-e063-6294a90a0cd3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:384a5cfb-05dd-2b79-73f4-a01a47a9eb3e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9c2d9f-62a8-4d26-a041-a598bc59e300 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c3ad9c1-474e-4331-a017-09cec46702d8 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02ddd5f5-76d3-4f1c-9af3-d39e05a19c29 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed1132ec-c2cd-4646-b69d-26663bb937a4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15d0a711-ef3b-4d93-8fbc-17a45f96af8a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a29b5c18-9884-4c88-8827-65d9ad5f69f6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10afd68b-877f-4819-a314-39f2d56d5db9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08db5ce7-4dcf-4581-a0bf-f405cc22b48d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79756604-56e6-d0ef-e053-2991aa0adc99 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:146b21e6-f8a5-47eb-b2d9-9ed70d1501d9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aeb533a-e72c-4af8-9867-b71d2eba9a49 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8603a9-5b6f-b921-e063-6394a90ae29c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b062fa9-e004-23d5-e053-2a91aa0a20cd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43e15d6-b778-7575-e053-2995a90a93a0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61758670-91ab-4422-8d9d-e8ca87eecae8 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26aff90c-49ea-46ac-bbf3-c188c2b061c9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef6ce203-4ae3-19c9-e053-2995a90af796 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b60074e5-8e77-4dc0-9244-4205e4adbaef (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40258e4b-5e67-46c0-8ef0-3e8bfe36ba11 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65b0b2e2-37fd-4d08-9674-954d62bb531a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70437694-0341-4f3b-824c-06843403443f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3207cf04-73b7-24ce-e054-00144ff8d46c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14276805-4e99-4bbe-ad76-ffc06eddb38a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ab3210e-eed1-479a-afc0-f72b5b776883 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a30d534-4607-4882-865e-56d2364acaad (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a0c4dc6-643e-4ee7-92a9-edb98049a5ba (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution: Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee668456-a214-4452-ab9d-ec00eaa41d79 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5ab38a2-5921-4320-a313-e0080c078046 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4feb4b89-2d2f-4a9c-a4f4-5ae3e26281b6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e41b9469-e844-47d9-933a-4c9f4453ecc7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:476e704c-95ae-4591-94f7-ee4ab827ff13 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67395789-0ac7-2244-e053-2a91aa0a652a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8d775b6-478c-499e-82be-bfdf006445e3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba0f8f13-1f7d-44e0-9c0f-0b43a9e8e3a7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89091629-d15e-4e95-aed8-8bc983c78302 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04800a86-2391-44e6-8763-d65e8a916c26 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution: Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72f29916-0f95-102d-e053-2991aa0aa5cd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57578387-1918-4e56-a564-f14fb22340bf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3efa5604-96c3-42a0-8e99-b3de4a66aa92 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9558d296-8edd-4aa1-875a-6247f9a8374d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:960e2104-18c3-4cfa-abf6-f1b30c452918 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:416be720-82e8-4a6d-8531-c1a29869daae (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35e0d160-813f-41d7-a382-d2cab6485d9c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30107d6f-5128-484f-b713-65244a98dc67 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:852a3251-bf28-5557-e053-2991aa0a4fbd (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1324076-f83e-4816-9e02-6b2a689010bc (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb02f2d7-31a9-4f12-880e-7ce7d85440d4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eee5217a-eba8-463a-812d-bf3c66f0934f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:561dce26-92fa-e00b-e063-6294a90a1ab2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50383ef5-6e6e-63a7-e054-00144ff88e88 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b7432b-f5a7-40f3-9b0c-e7b125f5103c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0050959-c14c-41b6-9a92-fadc5f6feff3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b50c1767-8a50-49ab-be31-6533021ae7c4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6694136-7591-4f23-8415-f2aa3c8bab40 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:834bc56a-657d-4733-9a60-47040cb5c7bf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65f01335-452e-42c6-a59b-4eb03badc55a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e09e262-dadf-4ae0-825e-448ea8dac174 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9913ed0c-aaad-45e1-b522-98ad170c2e8a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251d7b9a-f935-42f7-b985-91b8bba7637b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d1b8953-7ff5-4e91-ba97-3ba5c6ea8f71 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f08f56de-8678-4da9-8cae-013a5c393453 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac3dfb81-a4c7-4147-9374-c234153b7c51 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d89017aa-b8c3-4fd2-8e68-44e2cfd6f290 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e862601-1d8a-455b-8ce5-1a32478b309f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9ea1fc-59a4-8189-e063-6394a90a9ae6 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2c0e86c-e7fc-48f9-a894-02da8761001c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e87a5803-e872-43f7-8a15-79aa236e8c07 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f015e60-1aec-4ae7-b28f-42f6c8f50455 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66ac9c17-bea7-4f8d-8a27-a1e0f9e65945 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92c758a3-e749-4a15-be4b-ee30b364b2b0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37de0550-a6d1-46a8-a0b8-447b0dcf70ad (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a81a39b-051b-414e-a6b0-d844de4e9ab4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0be25a0-e13d-4242-93dc-0b86e82aadd7 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db9a0d22-9339-4319-e053-2a95a90a9592 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dff6676-e69e-779d-e053-2995a90a7c81 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d117de5f-64e5-464c-b782-de0f07e66c8e (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e24f935-87fe-4b6a-b265-60b1039f38d5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbe71308-2927-2467-e053-6394a90aa419 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a0cd50-aa4f-55bc-e053-2995a90a2d3a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b297c163-2052-cb22-e053-2995a90a8289 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:381b44e7-a5a1-42ad-bcea-1ab4c82ff5d4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a231919-6837-4b09-b66d-3706432b9702 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bde7c22c-0047-4735-8df6-b48e8dfa478a (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cd0c27-788d-5fd8-e053-2a91aa0a7c69 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b406d22-f1bf-460d-e063-6294a90a6b6f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4766235-ac44-ca93-78a6-66d4ded33ada (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2eeb3c61-4ce9-d8ed-e063-6294a90a00d3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38435346-d505-4bdd-bbc6-a7bcba411033 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:438c3d28-8bed-50f0-e063-6394a90a18e4 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76666e7e-3312-6f9d-e053-2991aa0af705 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:378d0963-d026-4478-8202-fbb636904a37 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db99c77a-0b01-9da6-e053-2a95a90a5199 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b96072-e8f2-4fd6-aaa0-b73fed214319 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4575d288-be0c-f6c3-e063-6294a90af708 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b0a1e5-5dfa-64a0-e063-6394a90acf36 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7975d78c-9bb6-467a-9c2d-ea15bde7af5c (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:822404ad-af08-4c62-ae38-7d9819e86079 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0862c02-781f-4b10-ae50-9c9c4ca26f6d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7949c245-b79f-4eaf-a75f-9a17bd7bd307 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f9fc8a2-0cfd-12f1-e053-2995a90acf3d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a62e2a6a-6235-7580-e053-2a95a90aa2b0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee1f115f-c8f8-4526-b827-c8e48aeb5050 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35716914-ac73-43c0-9aa0-09c99211d941 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e0e508-75f7-4c8b-bb38-898aa4c531c3 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c74336c-11ec-420a-80e1-d8e4a8f1c46d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81366c85-c6c9-4a9a-9fe5-cdd8c2d19f74 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cf8d4f-ac57-4177-e063-6394a90ae804 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b76c5cc9-f1ca-428b-8989-36a66802b650 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c4cda2f-13d9-42c5-b449-77deb06c8de5 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5566aebb-d84d-6d6a-e063-6294a90a746f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c29ca6df-621d-44b6-98fc-b48666573366 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bacb621-1261-25d9-e053-2991aa0afa3b (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64527de5-0b92-4340-9243-7a37e8ff96d9 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af735f22-6d6c-6e1f-e053-2a95a90a3532 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d71d26-0d42-b368-e063-6394a90add43 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf10d256-dd89-4a91-a3ed-81db505a79c2 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84234d20-aa73-446f-9a1b-846e0cb80cec (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:768aa02b-8231-5799-e053-2a91aa0a618d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89698ef8-62d3-77e4-e053-2995a90ab9db (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b675b09-fe40-435c-b91a-c61cdf767fbf (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:729d865f-d84a-495e-9456-4bceebb6e03f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dafe875e-391f-47a2-97b7-89840a760e44 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36592150-7e19-474c-9f96-cc8341e28b5d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58f16a00-3e66-29de-e053-2991aa0a59a0 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18063a64-a4c0-4bad-911b-00df5c7bb65d (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41366a20-0727-0446-e063-6294a90a957f (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0d827d0-333f-4187-ac75-9dc7d34b6169 (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f175a336-433b-7ab2-e053-2995a90ad5ca (opens source in a new tab)
Ondansetron label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.
Projected row 1137
- Medicine slug
- orlistat
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1 to 2 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6240792b-9224-2d10-e053-2a91aa0a2c3e (opens source in a new tab)
Orlistat label
Version not recorded · Effective date not recorded
Based on limited data, the half-life of the absorbed orlistat is in the range of 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f81dfaeb-46d5-47ce-9ef6-19259f5ac61c (opens source in a new tab)
Orlistat label
Version not recorded · Effective date not recorded
Based on limited data, the half-life of the absorbed orlistat is in the range of 1 to 2 hours.
Projected row 1138
- Medicine slug
- oseltamivir
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 74
- Source count
- 70
- Agreement rate
- 0.928571
- Recorded readings
1 to 3 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 65
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 65 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00e2e995-6296-b544-e063-6294a90a8345 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91eadf0b-5f04-4f5d-b095-02c5736a3647 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:432d9e7b-9cb2-4b7d-9fb2-015449096757 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92726a00-4237-49fd-9e29-5d4f5f999874 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9902b17-389b-45d4-b02f-67e35b0a5f3e (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd237e8-7ac9-f473-e063-6294a90aadfc (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c456f293-daf7-46b1-bffc-5ca234adbb70 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef093e4d-5b1a-463f-a1a3-b795a4387a81 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a70d9914-078f-4b4d-a1be-04669f7d0878 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40390bf9-f2c4-4608-b5c4-315457b92821 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7dd9f7f2-a887-454a-8d3e-761083b840db (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9307620-36bd-46c2-a8b2-027d3fba87ba (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b7a02ca-ee0e-4853-91e6-71a79f2bc040 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82685c2f-791b-440f-a1c2-5a032da7adca (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39255500-0ffd-4d72-abe8-257570b543e7 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a7181a6-e9eb-4047-a26f-4268f174db16 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f754ad7-9df0-4121-8051-0a09491be3c7 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c885cfb-46a0-4e18-ab96-03031b70b9d4 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40312c99-5374-41fa-a687-c70d97445e24 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1a280d0-4ce9-494a-9924-eb5621ce3757 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fbd0c56-82bf-f0fa-e063-6294a90a9f2f (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d8ce967-8037-9fd5-e053-2991aa0a015f (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd1d9f7-a4e0-7fda-e063-6294a90ad425 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73d7fa5a-8304-44b7-9456-58926a265d81 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:005b2784-e410-a50c-e063-6394a90a881c (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5194bb90-0876-48c4-a967-c862fbccd110 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e666061-1bfd-48cd-896b-ded8298a1847 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:196c8dee-342b-4627-b060-39b99ed91a41 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8a40f98-f6bd-4ef0-af03-93ed0f473c10 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad765459-e0d2-418e-8bae-8f6d16dfc1d8 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:497adf7b-9bdc-314e-e063-6394a90a63be (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37eb95bb-3142-4355-8057-4e7c78443641 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:613c8c4d-e647-4a4b-ac9b-c39aaa781ace (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea5bf8f-c3fa-4d44-bc3d-b1912374ee4b (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31c90a2e-9d14-4236-8dc2-b2a862e8cbac (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:817f74ca-2b6d-4d29-8dd5-b96921a23b91 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad90fe42-8d52-403e-9b07-b8536fbf335a (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fb09e82-42ef-4a2a-9bcd-3aab3ac52bb3 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c959361-8f08-4c65-968f-404a44422133 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de553d49-38c3-4fad-8582-d4d27c3c26b1 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee3c9555-60f2-4f82-a760-11983c86e97b (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:379f59fe-22d9-4bac-b9b5-31fdaebbd923 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1abef84-d074-4872-9193-48a52cbabbd6 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e81aaa7-7c40-4b05-b19a-cc70edd1d9f9 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0f71ac9-136c-4c8d-b30d-b8d08767c206 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d04f367-8f62-4f63-bac9-717d14f555a5 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b428e1f2-0082-4d9f-908e-e3633ea0457b (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dac3ba2-b667-4081-9395-8db45d38ceac (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00be0870-2ebb-46e3-9e98-a8f068ec664a (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89a3539b-a067-4073-b7a0-d04e7f130396 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a673aa2-e8f0-4aa4-8782-6fb3067ff108 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f26154bd-374c-44a8-983a-b2724a591653 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c754c2f7-7109-4498-aeee-c8ee088dfa98 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46dda802-32b8-4608-8eae-97e2cfc57472 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d306e22c-0cb8-46cb-9a40-8194a2bc9e85 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:339778ee-0b6f-6d81-e063-6394a90a2d32 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c61bb5af-558f-4b32-b34d-8fdae480443c (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07958a9a-2360-4380-b7da-5371ed80a271 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16fcbcb4-609c-4d4e-a134-013823207dc7 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd0236c6-317c-47b1-9185-3253dba4bb37 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d264c73-4dd9-4f7c-8a18-f31195cdd013 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78f85d27-9935-4775-b8d7-275e11429b76 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6f78d2d-6452-4af3-83c6-b044d1604bdc (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ca926e0-4c3c-473f-9cd0-ff38032d6963 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4dd9214a-6b7f-efe9-e063-6294a90ac4fb (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 to 3 hours in most subjects after oral administration.
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:809f859e-0852-80d3-1a67-da87ed399c15 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 hour to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27745acb-69a3-a1af-e063-6394a90ab10f (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 hour to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11cf45d4-0e6c-4408-bbe6-5ed94468cf2e (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of Oseltamivir declined with a half-life of 1 hour to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82df3237-636b-7bf9-3ba0-2b476e74bf4c (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 hour to 3 hours in most subjects after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1bec65b-4292-4110-a840-aa48053b5448 (opens source in a new tab)
Oseltamivir label
Version not recorded · Effective date not recorded
Plasma concentrations of oseltamivir declined with a half-life of 1 hour to 3 hours in most subjects after oral administration.
Projected row 1139
- Medicine slug
- oxacillin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
0.5 hours
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:152758c0-d225-4761-abeb-3f1cb0190806 (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4 (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d893e45b-7f18-4c67-b10c-1e2e52a6b3ef (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af2dccac-98c8-488f-a133-6374b3ca8dba (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:195c2054-0746-421d-8b20-8c751bdd772b (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4149d750-44e3-47e7-84f2-1e5cc839733b (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d37aae5-78d6-4b72-832a-7152c3a7068e (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4972ec74-1d9a-de9b-e063-6394a90af786 (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81e90279-9889-47bd-974b-334c181f295c (opens source in a new tab)
Oxacillin label
Version not recorded · Effective date not recorded
The elimination half-life for oxacillin is about 0.5 hours.
Projected row 1140
- Medicine slug
- oxaliplatin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 24
- Source count
- 24
- Agreement rate
- 1
- Recorded readings
90%
- Numeric value
- 90
- Unit
- %
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21a2bb1d-d91d-4f99-97dd-cc67fe99a090 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0799e39-7b1e-430a-b159-062b39521001 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b805925-beb1-2bac-e054-00144ff88e88 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6f89dc3-a594-4b5b-8728-272e20c1ecb5 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e38318e-c569-4ad4-8f10-a235f30444d1 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11377169-7986-45b1-8298-6f0533efa3c3 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9e47f3c-9acc-44f5-b0bd-d26fe9d35d64 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6083405-9b45-4d2c-e053-2995a90ad9ef (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee5a5a1d-63f6-4d5a-901b-65be45ec6610 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86f6c19d-30d1-42e3-8d46-5e3f45776e85 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f299b2d2-86ed-4fb8-822e-65455a0bb75a (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:873fa936-157a-4f85-bc70-5df31d71d122 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ac38523-480b-4c0f-97a1-7dfa1432923c (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee2e0da9-5ae7-405b-8dd1-635be72bc439 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fad0f147-6595-4412-87a7-2afca0192a96 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7dc8dfb1-dec8-43b3-b2ea-05eac054b2c6 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6178bc6-9dae-413f-8f47-de75d576c5b8 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d4f4b4-bb4e-46af-9e89-df20154436d0 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb4febd-0ed4-48c9-ba2a-e22183a2143f (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e51a62ba-d163-4c57-835c-8c86cf097e40 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab162009-6f84-4d56-ab56-5e84409ec814 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb180ec5-1f75-43c1-9f63-c0657af2ca5f (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da0e8523-609a-4326-96b1-d7de78662d91 (opens source in a new tab)
Oxaliplatin label
Version not recorded · Effective date not recorded
In patients, plasma protein binding of platinum is irreversible and is greater than 90%.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1130Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.